Physician profile
Alex Celluzzi
NPI 1770583536
$5,900.10
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $1,043 · 2021: $1,599 · 2022: $1,462 · 2023: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,159.22 | 2019-2023 | Xifaxan, Trulance |
| Abbvie INC. | $791.52 | 2019-2023 | Linzess, Creon, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $664.31 | 2019-2023 | Entyvio |
| Qol Medical, LLC | $571.21 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $325.45 | 2019-2023 | Simponi Aria, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $300.24 | 2019-2023 | Linzess |
| Celgene Corporation | $280.55 | 2021-2022 | |
| Romark Laboratories, Lc | $151.66 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $130.03 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $108.43 | 2019-2021 | |
| Alfasigma USA, INC. | $56.50 | 2020 | |
| Braintree Laboratories, INC. | $53.05 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $43.64 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $41.45 | 2019 | |
| Pfizer INC. | $39.58 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.76 | 2023 | Dificid, Zinplava |
| Ardelyx, INC. | $30.86 | 2023 | Ibsrela |
| Evoke Pharma, INC. | $27.06 | 2023 | Gimoti |
| Genzyme Corporation | $20.26 | 2023 | |
| Daiichi Sankyo INC. | $16.27 | 2023 | Injectafer |
| Medtronic, INC. | $15.27 | 2022 | |
| Redhill Biopharma INC. | $13.46 | 2020 | |
| Ucb, INC. | $13.22 | 2019 | |
| Dova Pharmaceuticals | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Celluzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.